TOT BIOPHARM International Company Limited (1875.HK)

HKD 1.65

(0.0%)

Market Cap (In HKD)

1.32 Billion

Revenue (In HKD)

780.62 Million

Net Income (In HKD)

-37.75 Million

Avg. Volume

21.56 Thousand

Currency
HKD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.48-2.79
PE
-
EPS
-
Beta Value
0.204
ISIN
HK0000545266
CUSIP
Y8899D101
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Jun Liu
Employee Count
-
Website
https://www.totbiopharm.com
Ipo Date
2019-11-08
Details
TOT BIOPHARM International Company Limited, an investment holding company, engages in the research and development, manufacture, and marketing of anti-tumor drugs in the People's Republic of China. The company's principal drug candidate is TAB008 for the treatment of non-squamous non-small-cell lung cancer metastatic colorectal cancer, glioblastoma multiforme, ovarian cancer, cervical cancer, and hepatocellular carcinoma. It also offers TOZ309 for malignant brain tumor. Further, the company develops TAA013 for HER2+ breast cancer which is under Phase III clinical trial; TAE020 which is under preclinical trial for acute myeloid leukemia; TAB014 for wet age-related macular degeneration and is under Phase II clinical trial. In addition, it develops TAY018 for non-Hodgkin's lymphoma, myelodysplastic syndrome, acute myelogenous leukemia, and solid tumors; TAC020 for various solid tumors; TEP118 for biliary cancer, gallbladder tumors, metastatic cancer, non-small-cell lung cancer (NSCLC), and gastric cancer; TOM312 for cancer and HIV-associated cachexia; TIC318 for epithelial-derived ovarian cancer, small-cell lung cancer, head and neck squamous cell carcinoma, testicular tumors, malignant lymphoma, cervical cancer, bladder cancer, and NSCLC; TVP211 and TID214 for solid tumors; and TIO217 for gastrointestinal tumors. TOT BIOPHARM International Company Limited was incorporated in 2009 and is headquartered in Suzhou, the People's Republic of China.